BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, Vermeulen W, Verhoeven C, Leav B, Zhang B, Sawlwin D, Hamers-Heijnen E, Edelman J, Smolenov I. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. Lancet Infect Dis 2021;21:1027-37. [PMID: 33577767 DOI: 10.1016/S1473-3099(20)30694-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Fulop T, Larbi A, Pawelec G, Cohen AA, Provost G, Khalil A, Lacombe G, Rodrigues S, Desroches M, Hirokawa K, Franceschi C, Witkowski JM. Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change. Vaccines 2022;10:607. [DOI: 10.3390/vaccines10040607] [Reference Citation Analysis]
2 Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, Fry AM. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021;70:1-28. [PMID: 34448800 DOI: 10.15585/mmwr.rr7005a1] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Palacios-Pedrero MÁ, Osterhaus ADME, Becker T, Elbahesh H, Rimmelzwaan GF, Saletti G. Aging and Options to Halt Declining Immunity to Virus Infections. Front Immunol 2021;12:681449. [PMID: 34054872 DOI: 10.3389/fimmu.2021.681449] [Reference Citation Analysis]
4 Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021;384:2187-201. [PMID: 33882225 DOI: 10.1056/NEJMoa2101544] [Cited by in Crossref: 176] [Cited by in F6Publishing: 129] [Article Influence: 176.0] [Reference Citation Analysis]
5 Zhang N, Li K, Liu Z, Nandakumar KS, Jiang S. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines. Viruses 2022;14:387. [DOI: 10.3390/v14020387] [Reference Citation Analysis]
6 Mattock R, Gibbons I, Moss J, Mealing S, Largeron N, Carroll S, Alvarez FP. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales. J Med Econ 2021;24:1261-71. [PMID: 34726129 DOI: 10.1080/13696998.2021.2000780] [Reference Citation Analysis]